Literature DB >> 26097610

Association of -308G/A and -238G/A polymorphisms of TNF-α and osteosarcoma risk.

Zhongwei Zhao1, Xiangyu Tang2, Kai Song2, Xiang Li3, Yonggang Zhang2.   

Abstract

OBJECTIVE: As a proinflammatory cytokine, TNF-α is associated with increased risk of osteosarcoma (OS). Our study aimed to explore the association of TNF-α polymorphisms and OS susceptibility in the Han Chinese population.
METHODS: 80 OS patients and 99 healthy people, matched on the age and sex, participated in the study. Genotyping was conducted by the method of polymerase chain reaction-restricted fragment length polymorphisms (PCR-RFLP). Then logistic regression was used to evaluate the effects of TNF-α polymorphisms (-308 G/A and -238 G/A) on the pathology of OS.
RESULTS: The frequency of AA genotype in -308 G/A locus in the cases was significantly higher than that of the healthy group (20.0% vs. 6.1%). Patients with OS were more likely to possess AA genotype of -308 G/A locus (OR=4.00, 95% CI=1.41-11.38). For the patients with A allele, the risk for OS increased 0.62 fold (OR=1.62, 95% CI=1.04-2.50). There was no remarkable relationship of -238 G/A polymorphisms and OS susceptibility. In addition, we found that patients with G-A and A-A haplotypes was much higher in the cases than that of control group (68.0% and 25.0%, 53.0% and 38.9%, respectively). A-G haplotype appeared to increase the risk for OS (OR=1.93, 95% CI=1.13-2.94).
CONCLUSION: The AA genotype of -308 G/A locus of TNF-α gene was a risk factor for OS, however there was no correlation between -238 G/A of TNF-α and OS.

Entities:  

Keywords:  -238G/A; -308G/A; TNF-α; osteosarcoma; polymorphisms; susceptibility

Mesh:

Substances:

Year:  2015        PMID: 26097610      PMCID: PMC4466997     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Polymorphism of the regulatory region of tumour necrosis factor alpha gene in patients with systemic lupus erythematosus.

Authors:  K Y Fong; H S Howe; S K Tin; M L Boey; P H Feng
Journal:  Ann Acad Med Singapore       Date:  1996-01       Impact factor: 2.473

3.  Investigation of cytokine gene expression in human colorectal cancer.

Authors:  M S Naylor; G W Stamp; F R Balkwill
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization.

Authors:  S Beissert; M Bergholz; I Waase; G Lepsien; A Schauer; K Pfizenmaier; M Krönke
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway.

Authors:  Caroline H Arnott; Kate A Scott; Robert J Moore; Alan Hewer; David H Phillips; Peter Parker; Frances R Balkwill; David M Owens
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

6.  Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha.

Authors:  F S Panagakos; L P Hinojosa; S Kumar
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

7.  Dexamethasone regulates IL-1 beta and TNF-alpha-induced interleukin-8 production in human bone marrow stromal and osteoblast-like cells.

Authors:  L R Chaudhary; L V Avioli
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

8.  Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD).

Authors:  G Bouma; B Xia; J B Crusius; G Bioque; I Koutroubakis; B M Von Blomberg; S G Meuwissen; A S Peña
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

9.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.

Authors:  V Kindler; A P Sappino; G E Grau; P F Piguet; P Vassalli
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

10.  Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue.

Authors:  D W Miles; L C Happerfield; M S Naylor; L G Bobrow; R D Rubens; F R Balkwill
Journal:  Int J Cancer       Date:  1994-03-15       Impact factor: 7.396

View more
  4 in total

1.  Association of TNF-α -308G > A polymorphism with susceptibility to tendinopathy in athletes: a case-control study.

Authors:  Lucas Rafael Lopes; Vitor Almeida Ribeiro de Miranda; João Antonio Matheus Guimarães; Gabriel Garcez de Araujo Souza; Victor Soares Wainchtock; João Alves Grangeiro Neto; Rodrigo de Araújo Goes; Jamila Alessandra Perini
Journal:  BMC Sports Sci Med Rehabil       Date:  2021-05-13

2.  Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review.

Authors:  Yanhua Jiang; Xiandi Wang; Yi Cheng; Jun Peng; Jiwei Xiao; Dingbo Tang; Ying Yi
Journal:  Oncotarget       Date:  2017-06-29

Review 3.  No association of TNF-α-308G/A polymorphisms with head and neck cancer risk: A PRISMA-compliant meta-analysis.

Authors:  Cheng Yuan; Xin-Hua Xu; Lu Xu; Yang Liu; Min Sun; Li-Hua Ni; Xiao-Long Wang; Zhuo Chen; Kun Zhang; Guang Zeng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

4.  Network Pharmacology Prediction: The Possible Mechanisms of Cinobufotalin against Osteosarcoma.

Authors:  Riyu Chen; Zeyi Guan; Xianxing Zhong; Wenzheng Zhang; Ya Zhang
Journal:  Comput Math Methods Med       Date:  2022-01-13       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.